Sam, Mofaisa .
HRN: 19-40-14 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/26/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
02/26/2023
03/05/2023
IVTT
115mg
Q8
T/Ccintestinal Ileus; R/0 Obstruction
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes